IS7-15 A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ)
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Thomas M, Salgia R, Wilner K, Bartlett C, Polli A, Gandara D. IS7-15 A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ). Annals Of Oncology 2012, 23: xi33. DOI: 10.1016/s0923-7534(20)32007-x.Peer-Reviewed Original ResearchObjective response rateMedian TTPPROFILE 1007Response rateLow objective response rateOngoing phase 3 trialsHigher objective response ratePhase 3 trialLarge retrospective analysisSingle-arm studySmall cohort studiesLarge phase 2High response rateAdenocarcinoma NSCLCBetter PFSCrossover patientsMedian PFSProgressive diseaseCohort studyNSCLC cohortRetrospective studyShorter TTPALK statusRetrospective analysisPemetrexed1267P A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Wilner K, Tang Y, Bartlett C. 1267P A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment. Annals Of Oncology 2012, 23: ix415. DOI: 10.1016/s0923-7534(20)33862-x.Peer-Reviewed Original ResearchNon-small cell lung cancerHigher overall response rateOverall response rateMedian TTPRetrospective analysisALK-positive non-small cell lung cancerBest overall response rateYounger ageLower overall response rateSmall retrospective cohortLarge retrospective analysisSingle-arm studyCell lung cancerSmall cohort studiesLarge phase 2Similar demographic characteristicsBristol-Myers SquibbAdenocarcinoma histologyBetter PFSCrizotinib treatmentPemetrexed activityClinical characteristicsCohort studyFormer smokersRetrospective cohort